ImPact Biotech to Present Updated Phase 3 Data on Padeliporfin VTP in Low-Grade UTUC at EMUC 2024

TEL AVIV, Israel, Oct. 25, 2024 – ImPact Biotech, a biotechnology company in its clinical stages, is working on the development of Padeliporfin vascular-targeted photodynamic (VTP) therapy, aimed at treating various solid tumors. The company recently disclosed that an abstract featuring interim outcomes from their ongoing Phase 3 study, ENLIGHTED, which focuses on Padeliporfin VTP therapy for low-grade upper tract urothelial cancer (UTUC), is set to be presented at the 16th European Multidisciplinary Congress on Urological Cancers (EMUC 2024). This congress is scheduled from November 7 to 10, 2024, and will be held in Lisbon, Portugal.

The abstract, titled "ENLIGHTED Phase 3 study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC)," will be presented by Gautier Marcq, M.D., M.Sc. It will be showcased as Poster Number P225 during the EMUC24 Networking and Abstract Discussion Session on November 9, 2024, at 17:30 GMT.

ImPact Biotech is dedicated to the innovation and commercialization of Padeliporfin VTP therapy, a minimally invasive treatment combining drugs and devices for the selective removal of solid tumors that cannot be surgically excised. This VTP platform employs non-thermal laser light delivered through optical fibers to activate Padeliporfin precisely within the tumor's microenvironment. Presently, Padeliporfin VTP is under assessment in a pivotal Phase 3 study for low-grade UTUC. Additionally, the company has other studies in earlier stages or planned for high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC).

ImPact Biotech maintains significant collaborations with renowned institutions such as the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center. The company operates in the European Union, Israel, and the United States.